Literature DB >> 21700605

Circulating fibrocytes are increased in children and young adults with pulmonary hypertension.

M E Yeager1, C M Nguyen, D D Belchenko, K L Colvin, S Takatsuki, D D Ivy, K R Stenmark.   

Abstract

Chronic inflammation is an important component of the fibroproliferative changes that characterise pulmonary hypertensive vasculopathy. Fibrocytes contribute to tissue remodelling in settings of chronic inflammation, including animal models of pulmonary hypertension (PH). We sought to determine whether circulating fibrocytes were increased in children and young adults with PH. 26 individuals with PH and 10 with normal cardiac anatomy were studied. Fresh blood was analysed by flow cytometry for fibrocytes expressing CD45 and procollagen. Fibrocyte numbers were correlated to clinical and haemodynamic parameters, and circulating CC chemokine ligand (CCL)2 and CXC chemokine ligand (CXCL)12 levels. We found an enrichment of circulating fibrocytes among those with PH. No differences in fibrocytes were observed among those with idiopathic versus secondary PH. Higher fibrocytes correlated to increasing mean pulmonary artery pressure and age, but not to length or type of treatment. Immunofluorescence analysis confirmed flow sorting specificity. Differences in plasma levels of CCL2 or CXCL12, which could mobilise fibrocytes from the bone marrow, were not found. We conclude that circulating fibrocytes are significantly increased in individuals with PH compared with controls. We speculate that these cells might play important roles in vascular remodelling in children and young adults with pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21700605      PMCID: PMC3319160          DOI: 10.1183/09031936.00072311

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  30 in total

Review 1.  The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond.

Authors:  Vibha N Lama; Sem H Phan
Journal:  Proc Am Thorac Soc       Date:  2006-06

2.  Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension.

Authors:  V S Nikam; R T Schermuly; R Dumitrascu; N Weissmann; G Kwapiszewska; N Morrell; W Klepetko; L Fink; W Seeger; R Voswinckel
Journal:  Eur Respir J       Date:  2010-06-04       Impact factor: 16.671

3.  New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis.

Authors:  Lei Sun; Marisa C Louie; Kevin M Vannella; Carol A Wilke; Ann Marie LeVine; Bethany B Moore; Thomas P Shanley
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-12-03       Impact factor: 5.464

4.  Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension.

Authors:  N Gambaryan; F Perros; D Montani; S Cohen-Kaminsky; M Mazmanian; J-F Renaud; G Simonneau; A Lombet; M Humbert
Journal:  Eur Respir J       Date:  2010-09-30       Impact factor: 16.671

5.  Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.

Authors:  Susan K Mathai; Mridu Gulati; Xueyan Peng; Thomas R Russell; Albert C Shaw; Ami N Rubinowitz; Lynne A Murray; Jonathan M Siner; Danielle E Antin-Ozerkis; Ruth R Montgomery; Ronald A S Reilkoff; Richard J Bucala; Erica L Herzog
Journal:  Lab Invest       Date:  2010-04-19       Impact factor: 5.662

6.  Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells.

Authors:  Neil J Davie; Joseph T Crossno; Maria G Frid; Stephen E Hofmeister; John T Reeves; Dallas M Hyde; Todd C Carpenter; Jacqueline A Brunetti; Ian K McNiece; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-05-16       Impact factor: 5.464

7.  Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension.

Authors:  Gerhard-Paul Diller; Sven van Eijl; Darlington O Okonko; Luke S Howard; Omar Ali; Thomas Thum; Stephen J Wort; Elisabeth Bédard; J Simon R Gibbs; Johann Bauersachs; Adrian J Hobbs; Martin R Wilkins; Michael A Gatzoulis; John Wharton
Journal:  Circulation       Date:  2008-06-02       Impact factor: 29.690

8.  Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis.

Authors:  Jeong Sup Song; Chun Mi Kang; Hyeon Hui Kang; Hyung Kyu Yoon; Young Kyoon Kim; Kwan Hyung Kim; Hwa Sik Moon; Sung Hak Park
Journal:  Exp Mol Med       Date:  2010-06-30       Impact factor: 8.718

Review 9.  Cellular and molecular basis of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Serge Adnot; Stephen L Archer; Jocelyn Dupuis; Peter Lloyd Jones; Margaret R MacLean; Ivan F McMurtry; Kurt R Stenmark; Patricia A Thistlethwaite; Norbert Weissmann; Jason X-J Yuan; E Kenneth Weir
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

10.  Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children.

Authors:  S Hall; P Brogan; S G Haworth; N Klein
Journal:  Thorax       Date:  2009-06-11       Impact factor: 9.139

View more
  29 in total

Review 1.  Advances in pediatric pulmonary arterial hypertension.

Authors:  Dunbar Ivy
Journal:  Curr Opin Cardiol       Date:  2012-03       Impact factor: 2.161

Review 2.  Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012.

Authors:  Daniel J Weiss
Journal:  Ann Am Thorac Soc       Date:  2013-10

Review 3.  Molecular pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

Review 4.  Concise review: current status of stem cells and regenerative medicine in lung biology and diseases.

Authors:  Daniel J Weiss
Journal:  Stem Cells       Date:  2014-01       Impact factor: 6.277

5.  Increased circulating fibrocytes are associated with higher reticulocyte percent in children with sickle cell anemia.

Authors:  Matthew S Karafin; Shibani Dogra; Mark Rodeghier; Marie Burdick; Borna Mehrad; C Edward Rose; Robert M Strieter; Michael R DeBaun; Robert C Strunk; Joshua J Field
Journal:  Pediatr Pulmonol       Date:  2015-06-30

Review 6.  Update on novel targets and potential treatment avenues in pulmonary hypertension.

Authors:  John C Huetsch; Karthik Suresh; Meghan Bernier; Larissa A Shimoda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-02       Impact factor: 5.464

7.  Implication of in vivo circulating fibrocytes ablation in experimental pulmonary hypertension murine model.

Authors:  Vandana S Nikam; Sandeep Nikam; Akyl Sydykov; Katrin Ahlbrecht; Rory E Morty; Werner Seeger; Robert Voswinckel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

8.  Biphasic presence of fibrocytes in a porcine hypertrophic scar model.

Authors:  Taryn E Travis; Matthew J Mino; Lauren T Moffatt; Neil A Mauskar; Nicholas J Prindeze; Pejhman Ghassemi; Jessica C Ramella-Roman; Marion H Jordan; Jeffrey W Shupp
Journal:  J Burn Care Res       Date:  2015 May-Jun       Impact factor: 1.845

9.  Cooperation between human fibrocytes and endothelial colony-forming cells increases angiogenesis via the CXCR4 pathway.

Authors:  David M Smadja; Peter Dorfmüller; Coralie L Guerin; Ivan Bieche; Cécile Badoual; Elisa Boscolo; Marianne Kambouchner; Aurélie Cazes; Olaf Mercier; Marc Humbert; Pascale Gaussem; Joyce Bischoff; Dominique Israël-Biet
Journal:  Thromb Haemost       Date:  2014-08-07       Impact factor: 5.249

Review 10.  Current challenges in pediatric pulmonary hypertension.

Authors:  Shinichi Takatsuki; David Dunbar Ivy
Journal:  Semin Respir Crit Care Med       Date:  2013-09-13       Impact factor: 3.119

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.